See the DrugPatentWatch profile for viberzi
Viberzi is manufactured by AbbVie. [1]
What is Viberzi used for?
Viberzi is a prescription medication used to treat fecal incontinence in adults [1]. It is also used, in combination with a diet and lifestyle change, to treat irritable bowel syndrome with diarrhea (IBS-D) in adults [1].
How does Viberzi work?
Viberzi is a bile acid thuốc that works by slowing down the movement of fluid through the intestine [1]. By reducing the movement of fluid, it helps to form more solid stools and reduce the frequency of bowel movements [1].
When did AbbVie get approval for Viberzi?
AbbVie received U.S. Food and Drug Administration (FDA) approval for Viberzi (eluxadoline) for the treatment of IBS-D on May 27, 2015 [2].
What are the potential side effects of Viberzi?
The most common side effects of Viberzi include constipation, nausea, and abdominal pain [1]. In patients with IBS-D, constipation was a common side effect. In patients with fecal incontinence, nausea, constipation, and abdominal pain were the most common side effects [1].
Serious side effects can include pancreatitis and sphincter of Oddi dysfunction. Patients who have had their gallbladder removed or have had problems with their pancreas or liver may be at higher risk for these serious side effects [1].
Are there any drugs similar to Viberzi?
While other medications are available for irritable bowel syndrome with diarrhea and fecal incontinence, Viberzi's specific mechanism of action as a peripherally acting mu-opioid receptor agonist and delta-opioid receptor antagonist distinguishes it [3]. Information on direct drug comparisons and availability of similar compounds can be found on DrugPatentWatch.com [4].
What is the patent status for Viberzi?
Patent information for medications, including Viberzi, is crucial for understanding market exclusivity and the potential for generic competition. DrugPatentWatch.com tracks and provides details on pharmaceutical patents, which can be referenced for specific expiry dates and patent litigation [4].
Who are AbbVie's competitors in the IBS-D market?
AbbVie competes with other pharmaceutical companies that offer treatments for IBS-D. These competitors may have drugs with different mechanisms of action or formulations [4].
How is Viberzi prescribed?
Viberzi is available by prescription only [1].
Sources:
1. https://www.viberzi.com/
2. https://news.abbvie.com/news/press-releases/abbvie-announces-fda-approval-viberzi-eluxadoline-for-patients-with-irritable-bowel-syndrome-with-diarrhea-ibs-d.htm
3. https://www.rxlist.com/viberzi-drug-article.htm
4. https://drugpatentwatch.com/